I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.
October 16, 2017
… It’s time!
For the oversold to be elevated to BUYS with a comeback from being smacked down
What’s the gauge of pricing expectation – monetization of information!
No subscription - you’re missing situational awareness!
Successful investing and trading means going upstream to obtain and quantify data to qualify actionable intelligence!
Pre-open indications: 1 SELL and 2 BUYs
October 13, 2017
Are day traders ready for the filed 8-K as BSTG conducted a reduction in headcount …
October 13, 2017
The pre-market indication was ... a positive +$6.25 or +7.25% … the fickle finger of sector and market acceptance
October 12, 2017
BTX prices $25 M offering at $2.60 and is trading at $2.63 down -4.03% (-$0.11)
October 16, 2017
What’s as valuable as clinical results? In this market, the credibility and authenticity of the management team backing their words with action, not always perfect yet adaptive through time, news events in development stages
How many times, do I have to say it; confidence enables momentum and ultimately pricing
Out and about: Athersys (ATHX -$ 0.07 or -3.23%) has agreed to settle its patent fight with Garnet Biotherapeutics and will pay Garnet $500K and issue it 1M shares of common stock plus $250K in each of the next four quarters … Funny how this issue never hit the news until after a substantial payment?
Pre-open indications: 3 hit and 0 miss
In the grip of rotating cycles and disparaging trends, what is the price of sector equities - knowledge and a subscription!
October 6, 2017
BSTG has been delisted from NASDAQ effective 10/6/17 to trade on the OTCQB, Pecos investment is in the wind and that ain’t all, what a MESS! Another nail in its cross of demise as CMO and President resigns while the company seeks any alternative ...
September 20, 2017
Shares closed up +$1.41 or +3.22 to $45.21 while the aftermarket drops -$1.95 or -4.31% 106,32 M shares outstanding a float of 70.66 M and a BIG shirt position of 15.43 M shares and 697.62 M in cash, 10 M indebtbut 82,57 M in revenue
August 31, 2017
VTGN is down -$0.10 or -5.50% to $1.72 A little heavy on the warrants to raise $2.4 million ...?
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
© 2017 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
